Human P-glycoprotein Contains a Greasy Ball-and-Socket Joint at the Second Transmission Interface*

Tip W. Loo, M. Claire Bartlett, and David M. Clarke

From the Departments of Medicine and Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Background: The human P-glycoprotein drug pump confers multidrug resistance.

Results: Hydrophobic suppressors in intracellular loop 2 restored activity to mutants with defective coupling between the ATP- and drug-binding domains.

Conclusion: A greasy “ball-and-socket” joint connects the ATP- and drug-binding domains.

Significance: This work identifies key component of the drug pump mechanism and a potential target to modulate this clinically important protein.

The P-glycoprotein drug pump protects us from toxins. Drug-binding sites in the transmembrane (TM) domains (TMDs) are connected to the nucleotide-binding domains (NBDs) by intracellular helices (IHs). TMD-NBD cross-talk is a key step in the transport mechanism because drug binding stimulates ATP hydrolysis followed by drug efflux. Here, we tested whether the IHs are critical for maturation and TMD-NBD coupling by characterizing the effects of mutations to the IH1 and IH2 interfaces. Although IH1 mutations had little effect, most mutations at the IH2-NBD2 interface inhibited maturation or activity. For example, the F1086A mutation at the IH2-NBD2 interface abolished drug-stimulated ATPase activity. The mutant F1086A, however, retained the ability to bind ATP and drug substrates. The mutant was defective in mediating ATP-dependent conformational changes in the TMDs because binding of ATP no longer promoted cross-linking between cysteines located at the extracellular ends of TM segments 6 and 12. Replacement of Phe-1086 (in NBD2) with hydrophobic but not charged residues yielded active mutants. The activity of the F1086A mutant could be restored when the nearby residue Ala-266 (in IH2) was replaced with aromatic residues. These results suggest that Ala-266/Phe-1086 lies in a hydrophobic IH2-NBD2 “ball-and-socket” joint.

ATP-binding cassette (ABC) membrane transport proteins couple ATP hydrolysis to the movement of a diverse range of substrates across cell membranes (1). They can act as importers or exporters or extract compounds from the lipid bilayer. A distinguishing feature of ABC proteins is that they contain at least two transmembrane domains (TMDs) with at least six transmembrane (TM) segments each and two nucleotide-binding domains (NBDs) that each contain a characteristic LSGGQ (signature) sequence.

Substrates of the 48 human ABC proteins include hydrophobic drugs, bile acids, ions, peptides, nucleosides, sterols, and carbohydrates. Human ABC proteins not only play important physiological roles, but mutations in at least 14 ABC transporter genes have been linked to hereditary diseases (2). Diseases include cystic fibrosis, adenoleukodystrophy, Tangier disease, Dubin-Johnson syndrome, Stargardt disease, age-related macular degeneration, and progressive familial intrahepatic cholestasis. Mutations can cause disease by disrupting activity, expression, folding, or trafficking of the proteins. In the case of drug pumps, overexpression can cause multidrug resistance. In addition, drug pumps can affect the pharmacokinetics of many drugs, and their modulation might also be useful in regulating the bioavailability of drugs (3).

The P-glycoprotein drug pump (P-gp, ABCB1) was the first human ABC protein to be discovered during efforts to determine how cancer cells developed multidrug resistance (4). P-gp was found to mediate the ATP-dependent efflux of a wide range of hydrophobic compounds (such as anticancer drugs, hydrophobic drugs, steroids, peptides, detergents, and lipids) that enter cells by diffusion through the plasma membrane (5, 6). P-gp is expressed in the epithelium of liver, kidney, and gastrointestinal tract and at the blood-brain or blood-testes barrier, where it functions to protect us from cytotoxic compounds. It is clinically important because it contributes to multidrug resistance in diseases such as cancer and AIDS (5). An important goal in P-gp studies is to understand the mechanism of drug efflux and use this knowledge to develop inhibitors aimed at overcoming multidrug resistance.

The 1280 amino acids of human P-gp (7) are organized as two tandem repeats of 610 amino acids that are joined by a linker region. Each repeat consists of an NH2-terminal TMD containing six TM segments followed by an NBD. Drug substrates appear to bind at multiple drug-binding sites within a cavity located at the interface between the TMDs (8–11). MgATP binds at the interface between the NBDs, which interact in a head-to-tail fashion. In this “nucleotide-sandwich conforma-

* This work was supported by grants from the Canadian Institutes of Health Research and the Canadian Cancer Society.
1 The recipient of the Canada Research Chair in Membrane Biology. To whom correspondence should be addressed: Dept. of Medicine, University of Toronto, 1 King’s College Circle, Rm. 7342, Medical Sciences Bldg., Toronto, Ontario M5S 1A8, Canada. Tel.: Fax: 416-978-1105; E-mail: david.clarke@utoronto.ca.
2 The abbreviations used are: ABC, ATP-binding cassette; BMOE, bis(maleimido)ethane; P-gp, P-glycoprotein; NBD, nucleotide-binding domain; TM, transmembrane; TMD, transmembrane domain; ICL, intracellular loop; IH, intracellular helix; CFTR, cystic fibrosis transmembrane conductance regulator; AMP-PNP, 5‘-adenylyl-β, γ-imidodiphosphate.
IH2 Mediates TMD/NBD Coupling in the P-gp Drug Pump

In this study, we first compared the effects of mutations to IH1 and IH2 on maturation of P-gp. None of the mutations in IH1 inhibited folding or activity of P-gp. By contrast, most mutations to IH2 inhibited P-gp maturation. Because mutant A266C/F1086C was inactive, we characterized the Ala-266/Phe-1086 interface to determine its role in the transport cycle. We report the identification of a potential “greasy” hydrophobic ball-and-socket connection at the IH2-NBD2 transmission interface critical for maturation and activity of P-gp.

EXPERIMENTAL PROCEDURES

Expression and Maturation of Mutants—Mutants were constructed to contain a polyhistidine (29) or A52 epitope tag at their C-terminal ends for use in whole cell immunoblot assays (26). The presence of the epitope tag distinguished the mutant proteins from any endogenous P-gp. P-gp contains three N-linked glycosylation sites that can be used to monitor maturation of human P-gp from an immature 150-kDa protein to a mature 170-kDa protein.

Mutations were introduced into the human P-gp cDNA as described previously (30). Mutants were expressed in HEK 293 cells for 18 h in the presence or absence of 10 μM cyclosporine A. Expression in the presence of drug substrates such as cyclosporine A (10 μM) or verapamil (25 μM) promotes maturation of processing mutants (31, 32). Whole cell extracts were subjected to immunoblot analysis using monoclonal antibody A52. The gel lanes were scanned, and the amount of mature 170-kDa product relative to total P-gp (immature 150-kDa P-gp plus mature) was analyzed using the National Institutes of Health Image program and an Apple computer.

Purification of P-gp and Measurement of ATPase Activity—Histidine-tagged P-gps were expressed in HEK 293 cells and then isolated by nickel-chelate chromatography as described previously (12). Recovery of P-gp was monitored by immunoblot analysis with rabbit anti-P-gp polyclonal antibody (12). A sample of the isolated histidine-tagged P-gp was mixed with an equal volume of 10 mg/ml sheep brain phosphatidylethanolamine (Type II-S, Sigma) that had been washed and suspended in TBS (pH 7.4). ATPase activity was measured in the presence of saturating concentration (0.6 mM) verapamil.

Effect of F1086A on Vanadate Trapping—The double cysteine mutant L443C/S909C was used to test whether the F1086A mutation inhibited vanadate trapping of nucleotide. Vanadate trapping inhibits cross-linking of L443C/S909C P-gp (20). Membranes prepared from cells expressing L443C/S909C or L443C/S909C/F1086A were incubated in the presence or absence of 5 mM MgATP plus 0.2 mM vanadate for 5 min at 37 °C. Samples were then treated with 1 mM copper phenanthroline for 15 min at 0 °C. The reactions were performed using a protein concentration of 0.4 mg/ml. The reactions were stopped by the addition of SDS sample buffer (125 mM Tris-HCl, pH 6.8, 20% (v/v) glycerol, and 4% (w/v) SDS) containing 5 mM EDTA and no thiol reducing agent. Samples of the reaction mixtures (1 μg of protein) were then subjected to SDS-PAGE (6.5% (w/v) polyacrylamide gels; 1.5-mm 15-slot minigels) and immunoblot analysis with a rabbit polyclonal antibody against P-gp. Intramolecular disulfide cross-linking between P-gp domains can be detected because the cross-linked product migrates with a slower mobility on SDS-PAGE gels (33).
IH2 Mediates TMD/NBD Coupling in the P-gp Drug Pump

Effect of Mutations on ATP-dependent Cross-linking of P-gp Extracellular Segments—Mutant T333C/L975C contains cysteines predicted to reside at the extracellular ends of TM segments 6 and 12, respectively (30). The double cysteine T333C/L975C constructs (with or without the F1086A or A266F mutations) were transiently expressed in HEK 293 cells. Membranes were prepared, suspended in TBS, pH 7.4, and treated with 0.5 mM bis(maleimido)ethane (BMOE) in the presence or absence of 5 mM MgATP, 5 mM MgADP, or 5 mM AMP-PNP for 5 min at 20 °C. The reactions were performed using a protein concentration of 0.4 mg/ml. The reactions were stopped by the addition of SDS sample buffer, and samples were subjected to immunoblot analysis. The positions of mature (170 kDa) and immature (150 kDa) forms of P-gp are shown. C, Percent Mature is the amount of mature protein relative to total P-gp. Each value is the mean ± S.D. obtained from three different transfections.

Viewing of Structures—The structures of P-gp were viewed using PyMOL (34).

RESULTS

Mutations in IH2 but Not IH1 Inhibit Maturation of P-gp— IH2 (residues Ile-261–Phe-267 in cytoplasmic loop 2 (ICL2)) is predicted to connect TMD1 to NBD2 (Fig. 1A) (17). TMD1-NBD2 interactions may be particularly important for folding of P-gp into a native structure during synthesis because a ΔNBD2 truncation mutant does not mature (28). By contrast, deletion of NBD2 in the CFTR protein, which has a similar structure to P-gp (30), yielded a mature product (28) that was as stable as its full-length counterpart (27).

To test whether IH2 was important for folding, the effect of mutations to residues Ala-259–Gln-270 (IH2 and flanking residues) on maturation was examined. Maturation of P-gp can readily be monitored using immunoblot analysis of whole cell extracts of transfected cells because P-gp is a glycosylated protein. P-gp contains three N-linked glycosylation sites in the extracellular loop that connects TM segments 1 and 2 (Fig. 1A). Mutations that inhibit folding trap P-gp as a 150-kDa core-glycosylated immature protein in the endoplasmic reticulum. Wild-type P-gp undergoes processing in the Golgi to yield a 170-kDa mature protein.

Most of the IH2 mutations (10 of 12) partially or completely inhibited maturation of P-gp (Fig. 1, A and C). The I261S, V264S, F267A, G268V, and G269V mutations blocked maturation such that the 150-kDa immature protein was the major product (Fig. 1B). Mutants A259L and A266L were similar to wild-type P-gp as the 170-kDa mature protein was by far the most prominent product. Mutants A260L, R262A, T263A, I265S, and Q270A yielded a mixture of mature and immature P-gp (Fig. 1, A and C).

IH1 (residues Ile-160–His-166) in ICL1 (connects TM segments 2 and 3) resides at the TMD1-NBD1 interface (Fig. 2A). In contrast to IH2, we found that none of the mutations introduced to IH1 and flanking residues (Gln-158–Gly-169) substantially inhibited maturation of P-gp (Fig. 2B).

Because IH1 mutations did not affect maturation, we tested whether some of the mutations affected activity. Mutants I160A, G161V, and D164A were selected for analysis because the recent high-resolution crystal structure of C. elegans P-gp showed that residues at these positions interacted with NBD1 (17). The histidine-tagged mutants were expressed in HEK 293 cells, isolated by nickel-chelate chromatography, and assayed for verapamil-stimulated ATPase activity. Verapamil was used because it is transported by P-gp (35) and it highly stimulates the ATPase activity of human P-gp (over 10-fold) (36). It was found that the activity of all three mutants was similar to that of wild-type P-gp (Fig. 2C).

The F1086A NBD1 Mutation Blocks ATP-dependent Extracellular Conformation Changes between the TMDs—Models of P-gp in the open and closed conformations are shown (Fig. 3, A and B). The major difference between the open and closed conformations is that the NBDs are far apart in the open conformation (Fig. 3A) but in close proximity in the closed conformation (Fig. 3B).

The models shown in Fig. 3, A and B, predict that Ala-266 in IH2 would be close to Phe-1086 in NBD2. In a previous study, we provided biochemical evidence that Ala-266 was indeed close to Phe-1086 in NBD2 because mutant A266C/F1086C showed robust cross-linking even when treated with oxidant at 0 °C to slow molecular motion (21). The Ala-266/Phe-1086 contact point appeared to be critical for function because mutant A266C/F1086C was inactive (21). By contrast, introduction of cysteine mutations at the equivalent sites between IH4 (S909C) and NBD1 (L443C) (Fig. 3, A and B) had no effect on activity (21).
To determine whether one or both cysteine mutations in mutant A266C/F1086C inhibited activity, mutants were constructed in a Cys-less background that contained only Cys-266 or Cys-1086. The mutants were expressed in HEK 293 cells in the presence of the drug substrate cyclosporine A (to promote maturation (32)), isolated by nickel-chelate chromatography, and assayed for verapamil-stimulated ATPase activity. It was observed that only the F1086C mutation caused a drastic reduction in verapamil-stimulated ATPase activity (Fig. 3 C).

An explanation for the ability of the F1086C mutation to inhibit P-gp activity was that the mutation affected folding of P-gp. To test whether the F1086C mutation inhibited folding, the F1086C mutant and the Y1087C mutant were expressed in the absence of drug substrates. The Y1087C mutant was included because an aromatic residue at position 1087 is highly conserved in ABC proteins (17). It was found that both the F1086C and the Y1087C mutations inhibited maturation of Cys-less P-gp (Fig. 3 D).

There are subtle differences in the activity of Cys-less P-gp when compared with the wild-type protein (37). In addition, it was possible that replacement of Phe-1086 with a cysteine caused a defect in the structure of P-gp that would be different if it had been replaced with a smaller amino acid. To test whether replacement of Phe-1086 with a small amino acid would affect maturation, mutants F1086A or Y1087A in the wild-type background were constructed and expressed in HEK 293 cells. Fig. 3 D shows that the Y1087A but not the F1086A mutation inhibited P-gp maturation (Fig. 3 D). Although the F1086A mutation did not inhibit folding, it still inhibited verapamil-stimulated ATPase activity (Fig. 3 C).

Why do changes to Phe-1086 inhibit P-gp verapamil-stimulated ATPase activity? To address this question, we first tested whether the F1086A mutation blocked interactions with ATP or verapamil.

FIGURE 2. Point mutations to IH1 do not inhibit P-gp maturation. A, the location of coupling helix IH1 between TMD1 and NBD1 is shown in the model. B, whole cell SDS extracts of HEK 293 cells expressing wild-type P-gp and P-gp mutants (mutations to IH1 and flanking regions) were subjected to immunoblot analysis. The positions of mature (170 kDa) and immature (150 kDa) forms of P-gp are shown. C, verapamil-stimulated ATPase activities of wild-type P-gp and mutants predicted to form contacts between IH1 and NBD1 in the C. elegans P-gp crystal structure (17). The results are the mean of three different transfections ± S.D.

FIGURE 3. Mutations to Phe-1086 inhibit P-gp activity. A and B, structures of P-gp in the open (A) (17) or closed (B) (24) conformations are shown. C, histidine-tagged Cys-less P-gp or mutants A266C/F1086C, A266C, and F1086C (in Cys-less background) as well as wild-type P-gp and mutant F1086A (in wild-type background) were isolated, and ATPase activities were measured in the presence of verapamil. Each value is the mean ± S.D. (n = 3). D, whole cell SDS extracts of cells expressing P-gp mutants (in Cys-less or wild-type background) were subjected to immunoblot analysis. The positions of mature (170 kDa) and immature (150 kDa) forms of P-gp are indicated. E, membranes prepared from cells expressing L443C/S909C/F1086A were first treated with (+VO4) or without (−VO4) MgATP plus vanadate. Samples were then treated with (+CuP) or without (−CuP) copper phenanthroline (CuP) and subjected to immunoblot analysis. The positions of the cross-linked (X-link) and mature (170 kDa) P-gps are indicated. F, the P709A processing mutation was introduced into mutant F1086A. Mutants were expressed in the presence (+Ver) or absence (−Ver) of verapamil (Ver), and whole cell extracts were subjected to immunoblot analysis.
It is possible that mutations to Phe-1086 could affect ATP interactions because the residue is close to the Walker A site in NBD2 (residues Ser-1077 to Gly-1084). To test whether mutant F1086A retained the ability to bind and hydrolyze ATP, we tested whether vanadate trapping of ATP would still inhibit cross-linking of mutant F1086A/L443C/S909C. P-gp can be trapped at a transition state during ATP hydrolysis by including vanadate in the reaction mix (35). Vanadate traps ATP at either NBD by mimicking the transition state of the γ-phosphate of ATP during hydrolysis, and trapping at one NBD inhibits ATP hydrolysis at the second site (35). Vanadate trapping of nucleotide causes conformational changes in P-gp, and this can be detected by disulfide cross-linking analysis (36). For example, vanadate trapping of nucleotide inhibits cross-linking of mutant L443C(NBD1)/S909C(IH4) (21). Accordingly, membranes prepared from cells expressing mutant F1086A/L443C(NBD1)/S909C(IH4) were preincubated with or without ATP plus vanadate for 5 min at 37 °C. Samples were then cooled on ice, treated with copper phenanthroline, and subjected to immunoblot analysis. Fig. 3E shows that vanadate trapping of nucleotide blocked cross-linking in both mutants L443C(NBD1)/S909C(IH4) and L443C(NBD1)/S909C(IH4)/F1086A. These results show that the F1086A mutation did not inhibit ATP hydrolysis.

A drug rescue assay was then used to test whether the F1086A mutation disrupted verapamil interactions with the TMDs. The rationale of the drug rescue assay is that expression of a P-gp processing mutant in the presence of verapamil will promote maturation if the mutant retains the ability to bind verapamil (32). Mutations that disrupt the verapamil-binding site will prevent rescue of processing mutants with verapamil (21). Accordingly, the F1086A mutation was introduced into the P709A processing mutant. The P709A mutant was selected because the mutation is located in the linker region that connects the two halves of P-gp and is outside the ATP- and drug-binding sites (Fig. 3, A and B). Expression of mutant P709A/F1086A yielded the 150-kDa immature form of P-gp as the major product (Fig. 3F). The mutant retained the ability to bind verapamil, however, because the mutant was rescued when expressed in the presence of verapamil such that the 170-kDa mature form of P-gp was the major protein product (Fig. 3F).

It is possible that the F1086A mutation inhibited activity by disrupting coupling between the NBDs and TMDs. Accordingly, cross-linking of mutant T333C/L975C was used to test the effect of F1086A on coupling. The T333C and L975C mutations are located at the extracellular ends of TM segments 6 and 12, respectively (Fig. 3, A and B). Mutant T333C/L975C can be cross-linked when intact cells expressing the mutant are treated with BMOE cross-linker (30). Mutant T333C/L975C, however, does not show cross-linking if membranes containing the mutant are treated only with BMOE (Fig. 4A). This suggested that ATP was required for cross-linking. Therefore, cross-linking of the mutant in membranes was carried out in the presence of ATP and other nucleotides. Fig. 4A shows that binding of ATP is required because cross-linking was observed in the presence of ATP or the nonhydrolyzable ATP analog AMP-PNP, but not in the presence of ADP (Fig. 4A). These results suggest that binding of ATP is coupled to a conformational change at the extracellular regions of P-gp that orient cysteines at 333(TM6) and 975(TM12) in positions that can be cross-linked with BMOE.

To determine whether the F1086A mutation affected NBD/TMD coupling, it was introduced into mutant T333C/L975C and subjected to cross-linking. It was observed that the F1086A mutation inhibited ATP-dependent cross-linking of the mutant T333C/L975C (Fig. 4B). These results suggest that F1086A disrupted NBD/TMD coupling.

Replacement of Phe-1086 with Bulky Hydrophobic Amino Acids Yields Active Mutants—Mutant F1086A was inactive (Fig. 3C). To test whether Phe-1086 was essential for activity, mutants were constructed such that Phe was replaced with a bulky hydrophobic (Tyr, Leu, Trp) or charged (Asp, Arg) amino acid. Fig. 5A shows that the F1086D or F1086R mutations inhibited maturation of P-gp. By contrast, those containing mutations of hydrophobic residues (F1086Y, F1086L, or F1086W) did not inhibit maturation. Mutants F1086D and F1086R could still be rescued if they were expressed in the presence of a drug substrate (Fig. 5B).

The histidine-tagged mutants were then purified and assayed for verapamil-stimulated ATPase activity. Mutants F1086D and F1086R were first expressed in the presence of cyclosporine A to promote maturation before isolating the histidine-tagged protein. It was observed that replacement of Phe-1086 with hydrophobic amino acids (Tyr, Leu, Trp) yielded active mutants, whereas replacement with charged amino acids yielded mutants with little activity (less than 10% of wild-type P-gp) (Fig. 5C). These results suggest that Phe-1086 can be replaced with a hydrophobic amino acid to yield a protein that matures to yield an active molecule.

Replacement of Ala-266 with Hydrophobic Residues Restores Activity of Mutant F1086A—Models (Fig. 3, A and B) and cross-linking results (21) predict that Ala-266 in IH2 is close to Phe-1086 in NBD2. Because a large hydrophobic amino acid might be required at the Ala-266/Phe-1086 interface for activity, we tested whether replacement of Ala-266 with the aromatic amino acids Tyr, Phe, or Trp could act as suppressor mutations to restore activity of the F1086A. We also predicted that replacement of Ala-266 with a small charged amino acid (Asp) would not restore activity to F1086A. It was found that replacement of Ala-266 with aromatic amino acids (A266Y, A266F or A266W) in the F1086A background yielded mature 170-kDa
P-gp as the major product (Fig. 6A). By contrast, mutant A266D/F1086A did not mature, although it could be rescued when expressed in the presence of cyclosporine A (Fig. 6B).

The histidine-tagged mutants were then isolated and assayed for verapamil-stimulated ATPase activity. Mutant A266D/F1086A was first expressed in the presence of cyclosporine A to promote maturation before isolating the histidine-tagged protein. Histidine-tagged mutants F1086D and F1086R were first expressed in the presence of cyclosporine A to promote maturation of P-gp before isolation of the protein by nickel-chelate chromatography. Each value is the mean ± S.D. (n = 3).

Replacement of Ala-266 with an aromatic amino acid might rescue defective TMD/NBD coupling and thereby restore activity to F1086A. Accordingly, the A266F mutation was introduced into mutant F1086A/T333C/L975C to test whether it affected cross-linking between the TMDs. It was found that the A266F mutation restored ATP-dependent BMOE cross-linking of the mutant (Fig. 6D).

**DISCUSSION**

The results show that IH2 is particularly important for folding of P-gp and coupling between the ATP- and drug-binding domains. For example, IH2 appears to be more important than IH1 for promoting TM1D interactions with the NBDs during synthesis. Most point mutations to IH2 reduced P-gp maturation efficiency (Fig. 1B), whereas none of the point mutations to IH1 inhibited maturation of P-gp (Fig. 2B). Comparison of P-gp with bacterial ABC transporters suggest that it might be expected that mutations to IH2 would have a greater effect on P-gp maturation than IH1 mutations because IH1-NBD1 interactions are not required for activity or synthesis of many bacterial ABC proteins (38).

A dynamic simulation study of human P-gp predicted that IH2-NBD2 interactions would be more important in driving the necessary conformational changes when compared with IH1 (39). It was found that IH2 made many more contacts with the NBDs when compared with IH1. It was also found that IH2-NBD2 interactions would be more important in driving the necessary conformational changes when compared with IH1 (39). It was found that IH2 made many more contacts with the NBDs when compared with IH1. It was also found that IH2 only interacted with NBD2, whereas IH1 contacted both the NBD1 and the NBD2 domains. The crystal structure of Sav1866 (homodimer) in a closed conformation also showed that IH2 contacted only an NBD in the opposite subunit, whereas IH1 made contact with the NBDs of both subunits (25). The crystal structure of *C. elegans* P-gp represents a snapshot of the protein in an open conformation with IH1 only in contact with NBD1 (17).

The recent crystal structure of P-gp from *C. elegans* also suggests that the contact between IH2-NBD2 is more important than between IH1-NBD1 (17). Only three amino acids in the IH1 region interacted with NBD1, whereas 14 amino acids were identified in the IH2 region (Glu-256–Glu-297, equivalent to amino acids to Glu-256–Glu-273 in human P-gp) that interacted with NBD2 via salt bridges, hydrogen bonds, or van der Waals interactions.
The results may also explain the puzzling difference between maturation of NBD2 deletion mutants of P-gp and its sister protein, CFTR. P-gp and CFTR are both ABC proteins predicted to have similar structures (30). Deletion of NBD2 in P-gp inhibits P-gp maturation, whereas deletion of NBD2 in CFTR does not. This study shows that P-gp maturation is highly sensitive to point mutations introduced at the TMD1/NBD2 interface. Most of the mutations introduced into IH2 inhibited maturation of the protein. Detailed analysis of the effect of IH2 mutations in CFTR have not yet been performed. Preliminary studies on the effects of ICL1 and ICL2 mutations in CFTR that cause cystic fibrosis have shown that the ICL1 mutations have more inhibitory effects on CFTR function (40).

The presence of hydrophobic amino acids at the ICL2-NBD2 interface appears to be critical for P-gp maturation and activity. Fig. 7 shows the locations of amino acids that when mutated, inhibited maturation and/or activity of P-gp. At least some of the mutations to the hydrophobic residues at Tyr-1087 or Phe-1086 in NBD2 or to hydrophobic residues at Ile-261, Val-264, Ala-266, or Phe-267 in IH2 inhibited maturation. Accordingly, we propose that a greasy hydrophobic IH2-NBD2 interface is critical for P-gp maturation and function. All of these residues, with the exception of Ile-261, were shown to participate in IH2-NBD2 interactions through hydrogen bonds or van der Waals interactions in the C. elegans crystal structure (17). It is possible that Ile-261 may be involved in contacts at another stage of the reaction or folding steps.

The effects of mutations to Ala-266 and Phe-1086 suggest that the presence of a hydrophobic interface between IH2 and NBD2 is also important for coupling of ATP interactions with the NBDs to conformational changes in the TMDs. Removal of Phe-1086 by mutation to alanine or replacement with charged amino acids inhibited activity and uncoupled ATP binding to conformational changes in the TMDs. Mutants were active if Phe-1086 was replaced with a hydrophobic amino acid. In addition, activity of the F1086A mutant could be restored if Ala-266 was replaced with an aromatic amino acid. Perhaps the presence of a greasy interface allows rotations of IH2 in the NBD2 cleft.

Studies of multiple crystal structures of the bacterial ABC maltose transporter suggest that its reaction cycle is accompanied by rotation of IH segments within the cleft of the NBDs (41). In addition, mutations to the IH-NBD interfaces disrupted activity and structure of the protein (42).

In summary, we identified a key hydrophobic interface between IH2 in TMD1 and NBD2. The interface is important for folding into a native structure during synthesis of the P-gp drug pump. The results also support the prediction that IH2-NBD2 site forms a ball-and-socket joint (17) that acts as a translocation interface (25) to couple the conformational changes associated with binding of ATP and drug substrates.

REFERENCES

1. Rees, D. C., Johnson, E., and Levinson, O. (2009) ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol. 10, 218–227
2. Kaminski, W. E., Piehler, A., and Wenzel, J. J. (2006) ABC A-subfamily transporters: structure, function, and disease. Biochim. Biophys. Acta 1762, 510–524
3. Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., van Deemter, L., Smit, J. J., van der Valk, M. A., Voordouw, A. C., Spits, H., van Tellingen, O., Zijlmans, J. M., Fibbe, W. E., and Borst, P. (1997) Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 94, 4028–4033
4. Juliano, R. L., and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152–162
5. Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., and Gottesman, M. M. (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol. 39, 361–398
6. Eckford, P. D., and Sharom, F. J. (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989–3011
7. Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47, 381–389
8. Aller, S. G., Yu, I., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., and Chang, G. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718–1722
9. Dey, S., Ramachandra, M., Pastan, I., Gottesman, M. M., and Ambudkar, S. V. (1997) Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 10594–10599
10. Lugo, M. R., and Sharom, F. J. (2005) Interaction of LPS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry 44, 643–655
11. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2009) Identification of residues in the drug-translocation pathway of the human multidrug resistance P-glycoprotein by arginine mutagenesis. J. Biol. Chem. 284, 24074–24087
12. Loo, T. W., and Clarke, D. M. (1995) Covalent modification of human P-glycoprotein mutants containing a single cysteine in either nucleotide-binding fold abolishes drug-stimulated ATPase activity. J. Biol. Chem. 270, 22957–22961
13. Sauna, Z. E., Kim, I. W., Nandigama, K., Kopp, S., Chiba, P., and Ambudkar, S. V. (2007) Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP·γS, a non-hydrolyzable analogue of ATP. Biochemistry 46, 13787–13799
14. Delannoy, S., Urbatsch, I. L., Tombline, G., Senior, A. E., and Vogel, P. D. (2005) Nucleotide binding to the multidrug resistance P-glycoprotein as studied by ESR spectroscopy. Biochemistry 44, 14010–14019

FIGURE 7. Model showing hydrophobic amino acids at the IH2-NBD2 interface critical for P-gp maturation and/or activity. Residues Val-253-Asn-278 (ICL2) and Val-1080-Pro-1089 (NBD2) are shown. The locations of residues Ile-261, Val-264, Phe-267, and Tyr-1087 are shown as mutation to aromatic residues restored the activity of F1086A. Residues Glu-256 and Arg-276 were recently shown to form a salt bridge that was critical for P-gp maturation (22).
IH2 Mediates TMD/NBD Coupling in the P-gp Drug Pump

15. Urbatsch, I. L., Sankaran, B., Weber, J., and Senior, A. E. (1995) P-glycoprotein is stably inhibited by vanadate-induced trapping of nucleotide at a single catalytic site. J. Biol. Chem. 270, 19383–19390
16. Gutmann, D. A., Ward, A., Urbatsch, I. L., Chang, G., and van Veen, H. W. (2010) Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends Biochem. Sci. 35, 36–42
17. Jin, M. S., Oldham, M. L., Zhang, Q., and Chen, J. (2012) Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 490, 566–569
18. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2004) Val-133 and Cys-137 mutations in the predicted cytoplasmic loops of P-glycoprotein. J. Biol. Chem. 279, 18232–18238
19. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2006) Transmembrane segment 1 of human P-glycoprotein contributes to the drug binding pocket. Biochem. J. 396, 537–545
20. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Suppressor mutations in the transmembrane segments of P-glycoprotein promote maturation of processing mutants and disrupt a subset of drug-binding sites. J. Biol. Chem. 282, 32043–32052
21. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2008) Arginines in the first transmembrane segment promote maturation of a P-glycoprotein processing mutant by hydrogen bond interactions with tyrosines in transmembrane segment 11. J. Biol. Chem. 283, 24860–24870
22. Loo, T. W., and Clarke, D. M. (2013) A salt bridge in intracellular loop 2 is essential for folding of human P-glycoprotein. Biochemistry 52, 3194–3196
23. Ravan, A. W., Sylte, I., and Sager, G. (2007) Molecular model of the outward facing state of the human P-glycoprotein (ABCB1), and comparison to a model of the human MRP5 (ABCC5). Theor. Biol. Med. Model. 4, 33
24. Glöbisch, C., Pajeva, I. K., and Wiese, M. (2008) Identification of putative binding sites of P-glycoprotein based on its homology model. ChemMedChem 3, 280–295
25. Dawson, R. J., and Locher, K. P. (2006) Structure of a bacterial multidrug ABC transporter. Nature 443, 180–185
26. Loo, T. W., and Clarke, D. M. (1994) Functional consequences of glycine mutations in the predicted cytoplasmic loops of P-glycoprotein. J. Biol. Chem. 269, 7243–7248
27. Cui, L., Aleksandrov, L., Chang, X. B., Hou, Y. X., He, L., Hegedus, T., Gentzsch, M., Aleksandrov, A., Balch, W. E., and Riordan, J. R. (2007) Domain interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365, 981–994
28. Wang, Y., Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2007) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol. Pharmacol. 71, 751–758
29. Loo, T. W., and Clarke, D. M. (1995) Rapid purification of human P-glycoprotein mutants expressed transiently in HEK 293 cells by nickel-chelate chromatography and characterization of their drug-stimulated ATPase activities. J. Biol. Chem. 270, 21449–21452
30. Loo, T. W., Bartlett, M. C., Detty, M. R., and Clarke, D. M. (2012) The ATPase activity of the P-glycoprotein drug pump is highly activated when the N-terminal and central regions of the nucleotide-binding domains are linked closely together. J. Biol. Chem. 287, 26806–26816
31. Loo, T. W., and Clarke, D. M. (1999) The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface. J. Biol. Chem. 274, 24759–24765
32. Loo, T. W., and Clarke, D. M. (1997) Correction of defective protein kinase of human P-glycoprotein mutants by substrates and modulators. J. Biol. Chem. 272, 709–712
33. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein: direct evidence for the substrate-induced fit mechanism for drug binding. J. Biol. Chem. 278, 13603–13606
34. DeLano, W. L. (2010) The PyMOL Molecular Graphics System, version 1.3r1, Schrödinger, LLC, New York
35. Omote, H., and Al-Shawi, M. K. (2002) A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein. J. Biol. Chem. 277, 45688–45694
36. Loo, T. W., Bartlett, M. C., and Clarke, D. M. (2003) Methanethiosulfonate derivatives of rhodamine and verapamil activate human P-glycoprotein at different sites. J. Biol. Chem. 278, 50136–50141
37. Taylor, A. M., Storm, J., Soceneantu, L., Linton, K. J., Gabriel, M., Martin, C., Woodhouse, J., Blott, E., Higgins, C. F., and Callaghan, R. (2001) Detailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type protein. Br. J. Pharmacol. 134, 1609–1618
38. Oldham, M. L., Davidson, A. L., and Chen, J. (2008) Structural insights into ABC transporter mechanism. Curr. Opin. Struct. Biol. 18, 726–733
39. Wise, J. G. (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51, 5125–5141
40. Seibert, F. S., Jia, Y., Mathews, C. J., Hanrahan, J. W., Riordan, J. R., Loo, T. W., and Clarke, D. M. (1997) Disease-associated mutations in cytoplasmic loops 1 and 2 of cystic fibrosis transmembrane conductance regulator impede processing or opening of the channel. Biochemistry 36, 11966–11974
41. Khare, D., Oldham, M. L., Orelle, C., Davidson, A. L., and Chen, J. (2009) Alternating access in maltose transporter mediated by rigid-body rotations. Mol. Cell 33, 528–536
42. Mourez, M., Hofnung, M., and Dassa, E. (1997) Subunit interactions in the ABC transporter mechanism. EMBO J. 16, 3066–3077